Repeatability of local forearm vasoconstriction to endothelin‐1 measured by venous occlusion plethysmography
Open Access
- 23 October 2002
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 54 (4) , 386-394
- https://doi.org/10.1046/j.1365-2125.2002.01653.x
Abstract
Aims We investigated the repeatability of the forearm blood flow response to intra‐arterial infusion of endothelin‐1 (ET‐1), assessed by venous occlusion plethysmography. Methods In eight healthy men (aged 18–50 years), on four separate occasions, ET‐1 (2.5 or 10 pmol min−1) was infused for 120 min via a 27 SWG cannula sited in the brachial artery of the nondominant arm. Each dose level was administered twice on consecutive visits. The dose order was randomized. Results are expressed as percentage change from baseline at 120 min (mean ± s.e. mean). Results ET‐1 caused significant vasoconstriction (P < 0.0001 anova) at both doses (38 ± 3%, 2.5 pmol min−1 and 62 ± 3%, 10 pmol min−1; mean visit 1 and 2). There was no difference in the response to either dose on repeated challenge. Responses appeared to be less variable when expressed as percentage change in the ratio of blood flow (infused:noninfused) in both arms than as percentage change in blood flow in the infused arm alone, as indicated by repeatability coefficients (15% vs 21%, 2.5 pmol min−1 and 11% vs 13%, 10 pmol min−1; ratio vs infused arm alone). Conclusions We have shown dose‐dependent vasoconstriction in the forearm vascular bed to intra‐arterial infusion of ET‐1 and that this response is less variable when expressed as percentage change in the ratio of forearm blood flow than percentage change in the infused arm. These data should also provide useful information to determine the power of early clinical pharmacology studies investigating the activity of endothelin receptor antagonists.Keywords
This publication has 38 references indexed in Scilit:
- Reduced endogenous endothelin-1–mediated vascular tone in chronic renal failureKidney International, 1999
- The endothelin system:a novel therapeutic target in cardiovascular diseaseEmerging Drugs, 1998
- The peptide endothelin receptor antagonist, TAK‐044, produces sustained inhibition of endothelin‐1 mediated arteriolar vasoconstrictionBritish Journal of Clinical Pharmacology, 1997
- Intra‐arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerabilityBritish Journal of Clinical Pharmacology, 1997
- Measuring Forearm Blood Flow and Interpreting the Responses to Drugs and MediatorsHypertension, 1995
- The Pharmacology of Human Blood Vessels in vivoJournal of Vascular Research, 1995
- Growth regulatory properties of endothelinsPeptides, 1993
- Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptorNature, 1990
- Cloning and expression of a cDNA encoding an endothelin receptorNature, 1990
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986